Editorial Article: Cancer immunotherapies: How single-cell sequencing can aid informed decision-making
An insider’s view on leveraging the latest single-cell technologies, including cell sorting and single-cell sequencing, to understand what drives response or resistance in checkpoint therapies
29 Apr 2021
Immune checkpoint blockade (ICB) therapies have revolutionized oncology treatment and become the standard of care in treating malignancies such as solid tumors
1,2. Despite proving more efficient than conventional chemotherapies or targeted therapies, due to their relatively high rate of response (up to 45% in melanoma patients), ICB presents challenges such as treatment resistance and eventual relapse. As cancer treatments evolve, some of the biggest unknowns in the field still are the factors driving the response or resistance to immunotherapy.